These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9250573)

  • 1. Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Eisenberg C
    Pharmacotherapy; 1997; 17(4):850-2. PubMed ID: 9250573
    [No Abstract]   [Full Text] [Related]  

  • 2. Validity of the GUSTO trial's main conclusion--author's reply. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Stringer KA
    Pharmacotherapy; 1997; 17(5):1043. PubMed ID: 9324198
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of acute ischemic stroke, Part 1.
    Fullerton T
    J Am Pharm Assoc (Wash); 1996 Oct; NS36(10):571-2. PubMed ID: 8908931
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular mechanisms of thrombolysis: implications for therapy.
    Collen D; Lijnen HR
    Biochem Pharmacol; 1990 Jul; 40(2):177-86. PubMed ID: 2115776
    [No Abstract]   [Full Text] [Related]  

  • 5. [GUSTO (Global Utilization of Streptokinase & t-PA for Occluded Coronary Arteries): comparison of four therapeutic strategies in acute myocardial infarction. Washington, 30 April 1993].
    Internist (Berl); 1993 Jul; 34(7 Suppl):1-12. PubMed ID: 7591608
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experience with the thrombolytic therapy of myocardial infarct].
    Gospodarenko AL; Ardashev VN; Tiurin VP; Chernetsov VA; Iakovlev VB; Vrublevskiĭ OIu; Makarenko AS; Sokolianskiĭ NV; Chernov SA; Kucherov VV; Davrent'eva TA
    Voen Med Zh; 1997 Nov; 318(11):40-5. PubMed ID: 9461835
    [No Abstract]   [Full Text] [Related]  

  • 7. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study.
    Krumholz HM; Gross CP; Peterson ED; Barron HV; Radford MJ; Parsons LS; Every NR
    Am Heart J; 2003 Nov; 146(5):839-47. PubMed ID: 14597933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombolytic therapy].
    Matsuda T
    Nihon Rinsho; 1998 Oct; 56(10):2577-81. PubMed ID: 9796322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue plasminogen activator (t-PA). Will it fulfill its promise?
    Sherry S
    N Engl J Med; 1985 Oct; 313(16):1014-7. PubMed ID: 3930959
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausärtze.
    Zahn R; Rustige J; Koch A; Schiele R; Burczyk U; Schuster S; Harmjanz D; Boppert D; Gottwik M; Neuhaus KL; Senges J
    Am J Cardiol; 1997 Nov; 80(10):1339-43. PubMed ID: 9388110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary thrombolysis.
    Thomas P; Sheridan DJ
    Q J Med; 1988 Sep; 68(257):657-63. PubMed ID: 2978484
    [No Abstract]   [Full Text] [Related]  

  • 12. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial.
    Karnash SL; Granger CB; White HD; Woodlief LH; Topol EJ; Califf RM
    J Am Coll Cardiol; 1995 Dec; 26(7):1651-6. PubMed ID: 7594099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations].
    Ardashev VN; Sokolianskiĭ NV; Bystrov VV
    Klin Med (Mosk); 2000; 78(12):28-30. PubMed ID: 11210347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator.
    de Bono DP
    Br J Hosp Med; 1986 Aug; 36(2):87. PubMed ID: 3091129
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the streptokinase responsible for the endothelial injury and the platelet activation during fibrinolytic therapy?
    Kolev K; Skopál J; Nagy Z; Machovich R
    J Intern Med; 2001 May; 249(5):475-6. PubMed ID: 11350572
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacology of coronary thrombolysis.
    Tiefenbrunn AI; Robison AK; Sobel BE
    Cardiol Clin; 1987 Feb; 5(1):125-8. PubMed ID: 3103917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
    Hasdai D; Topol EJ; Kilaru R; Battler A; Harrington RA; Vahanian A; Ohman EM; Granger CB; Van de Werf F; Simoons ML; O'connor CM; Holmes DR
    Am Heart J; 2003 Jan; 145(1):73-9. PubMed ID: 12514657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations.
    Krucoff MW; Green CL; Langer A; Klootwijk LJ; Trollinger KM; Sawchak ST; Wilderman NM; Veldkamp RF; Pope JE; Simoons ML
    J Electrocardiol; 1993; 26 Suppl():249-55. PubMed ID: 8189133
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombolysis in acute pulmonary embolism: to whom, how much and how?
    Jezek V
    Eur Heart J; 1997 Jul; 18(7):1045. PubMed ID: 9243132
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy.
    Barbagelata A; Califf RM; Sgarbossa EB; Knight D; Mark DB; Granger CB; Armstrong PW; Elizari M; Birnbaum Y; Grinfeld LR; Ohman EM; Wagner GS;
    Am Heart J; 2004 Nov; 148(5):795-802. PubMed ID: 15523309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.